Les misérables: a Parallel Between Antimicrobial Resistance and COVID-19 in Underdeveloped and Developing Countries.

Purpose of Review: The COVID-19 pandemic has been responsible for more than 6.3 million deaths worldwide. During the pandemic, the indiscriminate use of antibiotics has increased, contributing to the spread of multidrug-resistant bacteria. In this review, we aim to determine the spread and impact of antibiotic treatments in patients with COVID-19, focusing on underdeveloped and developing countries. Recent Findings: Meta-analysis revealed that bacterial co-infections and secondary infections are relatively rare in COVID-19 patients, corresponding to less than 20% of hospitalized patients. Even so, most of these patients have received antibiotic treatments. Summary: This review discusses how the COVID-19 pandemic could increase the emergence of multidrug-resistant strains to currently available antibiotics. Initially, we discussed the spread and impact of multidrug resistance of ESKAPE pathogens associated with nosocomial infections and analyzed their risk of secondary infections in patients with COVID-19. Then we highlight three factors related to the spread of resistant bacteria during the current pandemic: overprescription of antibiotics followed by self-medication. Finally, we discussed the lack of availability of diagnostic tests to discriminate the etiologic agent of a disease. All these factors lead to inappropriate use of antibiotics and, therefore, to an increase in the prevalence of resistance, which can have devastating consequences shortly. The data compiled in this study underscore the importance of epidemiological surveillance of hospital isolates to provide new strategies for preventing and controlling infections caused by multidrug-resistant bacteria. In addition, the bibliographic research also highlights the need for an improvement in antibiotic prescribing in the health system.

Introduction

In 2020, the World Health Organization (WHO) declared that the outbreak of the newly identified severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), a strain of coronavirus and the etiological agent of the coronavirus disease (COVID-19). The disease constituted an international public health emergency [1]. The new coronavirus quickly spread worldwide, and outbreaks of COVID-19 have been reported by several countries and regions of the world. In mid-March 2020, the WHO declared COVID-19 a pandemic. As of June 14, 2022, more than 532 million confirmed cases and more than 6.3 million deaths had been reported from the COVID-19 pandemic. In late 2020, the efforts of scientists around the world resulted in the development of safe and efficient vaccines against COVID-19. With the availability of these vaccines, the number of cases and deaths began to progressively decrease, indicating that mass vaccination can contain outbreaks of COVID-19 [2, 3], also showing the possibility of the end of the COVID-19 pandemic.

Although we are probably close to the end, it is believed that in the future, we will have to deal with many problems arising from the COVID-19 pandemic. One of the possible problems that we will have to face is the increase in antimicrobial resistance [4•]. Resistance is currently the biggest problem with antimicrobials and one enormous burden on the public health system worldwide. A recent study analyzed the worldwide prevalence of antimicrobial resistance and estimated that 4.95 million deaths were associated with antimicrobial resistance in 2019, among which 1.27 million were directly attributable [5]. Treating patients with antimicrobial resistance is associated with high economic costs due to prolonged hospitalizations, high cost of second-line antibiotics, additional detection testing to identify pathogens, and decreased productivity, representing a tremendous burden on the economy of countries. It is estimated that by 2050 antimicrobial resistance will be responsible for the death of approximately 10 million people worldwide [5, 6] at the cost of between $300 billion to $10 trillion [7]. Some authors estimate that the capital loss will be $100 trillion [6]. Therefore, antimicrobial resistance could increase poverty in countries, especially in underdeveloped or developing countries.

The discovery of antimicrobials in the nineteenth century revolutionized medicine and considerably increased half-life worldwide. Infectious diseases represented one of the leading causes of death in the early nineteenth century. However, this changed with the era of antibiotics [8], starting in 1943 with the approval and commercialization of penicillin. After the commercialization of antibiotics, the half-life increased significantly, and the mortality rate associated with infectious diseases decreased. For example, in 1920, the life expectancy in the USA was 56.4 years, and today it has risen to 80 years [9]. However, a few decades after the discovery of antimicrobials, the first antibiotic resistances began to be described, and even at least 3 years before the commercialization of penicillin, penicillin-resistant strains of Staphylococcus aureus were reported in the literature [10]. In 1950 resistance to beta-lactam penicillin was described. Later in 1962, a methicillin-resistant strain of S. aureus was identified. Later strains resistant to tetracycline, gentamicin, erythromycin, levofloxacin, and vancomycin were also reported [10]. Bacteria have now developed multiple resistances to most available antibiotics.

This antimicrobial resistance occurs due to genetic changes in bacteria. Although antibiotic resistance is a naturally occurring event, it is often potentiated and caused by the overuse of antibiotics, causing them to lose their effectiveness [11]. As a result of this resistance, infections caused by these agents become challenging to treat. This, in turn, increases the risk of the disease spreading, resulting in more severe cases and deaths. In addition, the emergence and spread of resistant pathogens threaten our ability to treat previously common infections [2, 12•, 13•]. Based on this precept, the WHO has released a list of drug-resistant bacteria that pose the greatest threat to human health [2], categorizing them as critical, high, and medium priority organisms in terms of antimicrobial resistance.

Studies show that the indecency of infections caused by multidrug-resistant microorganisms resistant to multiple antibiotics occurs worldwide regardless of income [14•]. However, the regions most affected by this problem are the poorest and most populous on the planet [14•, 15]. According to a study carried out by Wirtz et al. [16], in the 10 years, from 1997 to 2007, there was an increase in resistance to several classes of antimicrobials in Latin America, mainly quinolones, corroborating the data found in the 2020 systematic review [17] that demonstrated the existence of 9 different genes related to the quinolone resistance plasmid in Latin America. In addition, Domínguez et al. [18] showed resistance to beta-lactams in aquatic environments also in Latin America.

In parallel with the emergence of antibiotic resistance, the development and approval of new antimicrobials have declined dramatically over the years [11, 19]. The WHO published in January 2020 a report on studies with new antibiotics at preclinical and clinical levels. The study showed that only 52 new antimicrobial compounds are being tested. Even more alarming data showed that only 32 of these were aimed at treating multidrug-resistant pathogens considered a priority by the organization [20•].

In addition, since the beginning of the COVID-19 pandemic, antibiotic consumption worldwide has increased, and researchers are warning of a possible rise in antibiotic-resistant strains and an increase in multidrug-resistant strains of concern, globally, such as strains of the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) [13•, 21]. Therefore, this review aims to describe recent data on the COVID-19 pandemic and its impact on the appearance of multidrug-resistant strains of the ESKAPE group, focusing mainly on underdeveloped and developing countries. This study uses PubMed, Web of Science, Science Direct, LILACS, and SciELO databases. To search for data regarding the impact of the COVID-19 pandemic on antibiotic resistance, “COVID-19” and “antibiotic resistance” were used to search for data. The articles found were analyzed and the data described in this study. This review suggests strict surveillance and implementation of antimicrobial resistance control policies. It indicates the need for research focused on understanding the impact of the COVID-19 pandemic on antimicrobial resistance in the coming years, especially in underdeveloped and developing countries, as well as the implementation of molecular biology tools for diagnosing bacterial infections.

Spread and Impact of Diseases Caused by Multidrug-Resistant Bacteria Around the World

According to Murray et al. [14•], approximately 5 million deaths associated with multidrug-resistant bacteria occurred worldwide in 2019. Also according to Murray et al. [14•], the most affected regions are Africa, where approximately 400 deaths per 100,000 inhabitants are reported, followed by America, Asia, Europe, and Oceania. The regions with the highest deaths are, not coincidentally, the poorest regions on the planet [15]: sub-Saharan Africa, with 375 deaths per 100,000 inhabitants, and South Asia, with 80 deaths per 100,000 inhabitants [14•]. South America is the fourth subregion on the list, with about 75 deaths caused by multidrug-resistant bacteria for every 100,000 inhabitants [14•].

In underdeveloped or developing countries, factors such as (I) inadequate access to effective drugs, (II) unregulated administration and manufacturing of antimicrobials, and (III) truncated antimicrobial therapy due to cost are contributing to the development of multidrug-resistant organisms [15]. Furthermore, the causes of antimicrobial resistance in developing countries are complex and may be related to (I) the practices of health professionals, (II) the behavior of patients concerning the use of antimicrobials, and (III) the antimicrobial supply chain. These factors may include poor prescribing practices, inadequate patient education, limited diagnostic facilities, unauthorized sales of antimicrobials, lack of adequate drug regulatory mechanisms, and non-human use of antimicrobials [22].

ESKAPE Pathogens Cause Most of the Hospital-Acquired Infections in the World

In February 2017, to focus on and guide research and development related to new antibiotics, the WHO published its list of pathogens for which antimicrobial development is urgently needed [2]. This comprehensive list has designated ESKAPE pathogens as “priority status” [23]. The ESKAPE group comprises multidrug-resistant strains that are the main causative agents of nosocomial infections worldwide [24].

ESKAPE pathogens have developed resistance mechanisms against oxazolidinones, lipopeptides, macrolides, fluoroquinolones, tetracyclines, β-lactams, combinations of β-lactam inhibitors, and antibiotics that are the last line of defense, including carbapenems, glycopeptides, and polymyxins [25-27]. The acquisition of resistance occurs through random genetic mutations and/or the acquisition of mobile genetic elements such as transposons and plasmids (Table 1) [28, 29].

Table 1

Pathogen, virulence factor, and antibiotic resistance reported in patients with COVID-19 and secondary bacterial infections

Pathogen	Virulence factor	Antibiotic resistance reported	Reference
E. faecium	Cytolysins, gelatinase, aggregating substances, hyaluronidase, surface protein, membrane proteins	β-lactams, aminoglycosides, fluoroquinolones, glycopeptides	[30, 31]
S. aureus	Biofilm, toxins (cytotoxins and enterotoxins), hemolysins, cytolysins, immune evasion factors	β-lactams, fluoroquinolones, glycopeptides	[32–35]
K. pneumoniae	Capsular polysaccharide, lipopolysaccharide (LPS), type 1 and type 3 fimbriae, outer membrane protein, biofilm	β-lactams, carbapenems	[36, 37, 37–46]
A. baumannii	Pilus, iron absorption and metabolism, quorum sensing, type IV secretion system, lipopolysaccharide, phospholipase D expression, capsular polysaccharide, biofilm	Aminoglycosides, β-lactams, fluoroquinolones, polymyxins	[47–58]
P. aeruginosa	Biofilm, elastase production, phospholipase C, protease A, exotoxins, cytotoxins, flagella, quorum sensing	β-lactams, carbapenems, aminoglycosides	[59–61]
Enterobacter spp.	Somatic antigens, adhesins, serum resistance, enterotoxins, colicins, hydrophores, hemolysins	Penicillins, cephalosporins, carbapenems, fluoroquinolones	[62, 63]

Before the pandemic, a study by Zhen et al. [64] evaluated the economic impact of antibiotic resistance in organisms of the ESKAPE group. The authors observed that the most studied organism is S. aureus, followed by Enterococcus spp., A. baumannii, K. pneumoniae, and P. aeruginosa. Approximately 85% of the studies eligible for analysis assessed the total hospital cost, 14% the cost of antibiotic treatment, and 5% the cost in intensive care units. Overall, the authors observed that multidrug-resistant organisms are significantly associated with more economic burdens than susceptible organisms or those without infection or colonization. Indeed, Marturano and Lowery (2019) [65] determined that the total cost of care for patients with infections caused by pathogens in the ESKAPE group is higher than for those with non-ESKAPE pathogens by an average of $5500.

ESKAPE group pathogens constitute a significant healthcare burden, and recent studies suggest upward trends in prevalence [66], economic cost [67], and resistance [68] in the coming years.

A bibliometric study by Ayobami et al. [69•] evaluated antibiotic resistance in nosocomial infections caused by bacteria from the ESKAPE group in low- and middle-income countries between 2010 and 2020. The authors observed that the proportion of methicillin resistance pooled in S. aureus was 48.4%. In addition, the pooled proportions of carbapenem resistance were higher in Gram-negative pathogens: K. pneumoniae (34.9%), A. baumannii (72.4%), P. aeruginosa (37.1%), and Enterobacter spp. (51.2%). Furthermore, third-generation cephalosporins were observed with higher proportions of resistance in K. pneumoniae (78.7%) and Enterobacter spp. (83.5%). In summary, the combined resistance ratios for Gram-negative pathogens were higher in low- and middle-income countries than regional and national estimates from high-income countries. This study demonstrated that patients in resource-limited regions are particularly affected by antimicrobial resistance, which has been previously reported [15]. The authors further suggested that to combat high antibiotic resistance in low- and middle-income countries and reduce health disparities, strengthening local surveillance and health systems, in general, is crucial.

Patients with COVID-19 Are at Risk of Secondary Infections by ESKAPE Pathogens

Bacterial infections are commonly identified in patients with viral respiratory infections and are important causes of morbidity and mortality in patients infected with SARS-CoV-2 [70•]. Therefore, it is essential to differentiate between co-infection and secondary infection. Co-infections are present in the patient at admission, while secondary infections are acquired during hospitalization. Patients with COVID-19 are more likely to develop secondary infections during hospitalizations [71]. However, in clinical practice, it is not very common to differentiate whether a patient with COVID-19 has a co-infection or has acquired a secondary infection due to the lack of initial diagnostic tests (this topic will be discussed later). In any cases of bacterial infection in patients with COVID-19 (secondary infection or co-infection), the patients need to be treated with antibiotics (Table 2) [70•].

Table 2

Meta-analysis summary of ESPAKE group bacteria isolated in COVID-19 patients

Patients evaluated for bacterial infection (%)	Patients that received antibiotics (%)	Patients with bacterial infection (%)	Patients with co-infection (%)	Patients with secondary infection (%)	Microorganisms of the identified SKAPE group	Reported treatments	Reference
3338	71.9%	7.7%	3.8%	14.3%	P. aeruginosa	Fluoroquinolones and 3rd cephalosporins	[72•]
3834	> 90%	7%	NR	NR	P. aeruginosa	Moxifloxacin, Cephalosporins, quinolones, carbapenems, tigecycline, linezolid, ceftriaxone, amoxicillin, beta-lactams levofloxacin, azithromycin	[73]
558	28–79%	33% (by BioFire PNplus) 18% (culture-based detections)	NR	NR	Enterobacterales, S. aureus, P. aeruginosa, A. calcoaceticus-baumannii complex	3rd-generation cephalosporin	[77]
8.249	NR	25,6%	NR	NR	S. aureus	NR	[78]
NR	98%	NR	8%	20%	K. pneumoniae, S. aureus, Acinetobacter spp., Pseudomonas (10,8%)	NR	[79]

A study by Langford et al. [72•] evaluated 3338 patients with COVID-19. Among these, 3.5% had acute bacterial co-infections, and 14.3% had secondary bacterial infections. The overall proportion of COVID-19 patients with bacterial infection was 6.9%. The authors also observed that bacterial co-infection was more common in critically ill patients, accounting for 8.1%; however, most COVID-19 patients received antibiotic treatment.

Another study by Lansbury et al. [73], including 3834 patients, observed that 7% of hospitalized patients with COVID-19 had a bacterial co-infection and/or secondary infection. As Langford et al. [72•] and Lansbury et al. [73] observed, a more significant proportion of patients in intensive care units (ICU) had bacterial infections (14%) than patients in mixed ward/ICU settings (4%).

Also, Gaspari et al. [74] evaluated 173 patients in the COVID-19 period and 132 in the pre-COVID-19 period. Co-infections and/or secondary infections with pathogens from the ESKAPE group were documented in 23 (13.3%) and 35 (26.5%) patients in the pandemic and pre-pandemic periods, respectively. Poyil [75•] also assessed the prevalence of bacterial infections with ESKAPE pathogens in patients with COVID-19. Finally, the author observed several studies that reported bacterial infections with COVID-19 at various levels. The causative agents included multidrug-resistant strains from high-priority categories such as vancomycin-resistant Enterococcus, intermediate/vancomycin-resistant Enterococcus faecium, vancomycin- and methicillin-resistant S. aureus, extended-spectrum beta-lactamases-producing K. pneumoniae, A baumannii resistant to carbapenems, and P. aeruginosa producing extended-spectrum beta-lactamases.

Bacterial infections are relatively infrequent in hospitalized patients with COVID-19, less so than in previous flu pandemics. Thus, most of these patients may not require empirical antibacterial treatment, which does not support the routine use of antibiotics in managing confirmed COVID-19 infection. Most bacterial infections, whether or not they belong to the ESKAPE group, are more frequently associated with more severe disease cases (Table 3). Thus, there has been concern about the worsening of antimicrobial resistance in patients with COVID-19, as the choice of antibiotics in patients with the disease is often empirical [76].

Table 3

Summary of resistance and complications associated with secondary infections caused by MDR ESKAPE pathogens in COVID-19 patients from underdeveloped and developing countries

MDR pathogen	Resistance	Complication	Reference
E. faecium	Gentamicin, erythromycin, kanamycin, tetracycline, tobramycin, and vancomycin	Pleural effusion, bloodstream infection	[80–82]
S. aureus	Ciprofloxacin, gentamicin, methicillin, oxacillin, penicillin, tetracycline, vancomycin	Cervical abscess, bloodstream infection	[83–86]
K. pneumoniae	Amikacin, ampicillin, aztreonam, cefepime, cefotaxime, cefuroxime, ciprofloxacin, gentamycin, imipenem, polymyxin b, tobramycin	Pulmonary infection, urinary tract infection, bloodstream infection	[84, 87–90]
A. baumannii	Ampicillin, ertapenem, gentamicin, imipenem, meropenem, polymyxin B	Pulmonary infection, urinary tract infection, wound infection, gastrointestinal colonization, bloodstream infection	[84, 91–94]
P. aeruginosa	Cefazolin, cefroxadine, ceftazidime, imipenem, piperacillin/tazobactam	Pulmonary infection, urinary tract infection, spondylodiscitis, bloodstream infection	[93–97]
Enterobacter spp.	Amikacin, ciprofloxacin, colistin, ertapenem, imipenem, meropenem, penicillin, sulfamethoxazole-trimethoprim	Urinary tract infection, bloodstream infection	[38, 94, 98]

NR not reported

Factors Associated with the Appearance and Spread of Antibiotic-Resistant Bacteria During the COVID-19 Pandemic

Excessive and Reckless Medical Prescription in the COVID-19 Pandemic

One of the strategies implemented to combat COVID-19 is using antibiotics in some severe cases, but inappropriately prescribing antibiotics to patients with COVID-19 could generate antibiotic resistance and compromise efforts in the fight against antimicrobial resistance, which could have devastating consequences shortly. For example, patients with respiratory infections other than COVID-19 and who had symptoms similar to COVID-19, as well as efforts to prevent the spread of COVID-19, have led to the empirical use of antibiotics in hospitals [99]. Given the empirical use of antibiotics, the WHO recommends administering antibiotics only for severe cases of COVID-19 or when there are signs and symptoms of bacterial infection. However, many patients with mild COVID-19 without pneumonia or moderate COVID-19 with pneumonia receive antibiotics [21, 72•]. Previous studies have associated higher mortality in patients due to bacterial co-infections in influenza [100]. In addition, death cases of patients with COVID-19 along with bacterial co-infections have also been frequently reported [101]. However, the available evidence suggests that in both influenza and COVID-19 cases, rates of bacterial co-infection are low (less than 20%).

In three studies conducted in Wuhan of hospitalized patients with COVID-19, it was reported that most patients received antibacterial therapy. In the first study of 191 patients, 95% received antibiotics. In the second study, 72% of the patients were treated with antibiotics. Still, only 8% showed bacterial or fungal co-infections. In the third study, all patients in a hospital received antibacterial therapy with an antibiotic or a combination of antibiotics [101-103]. Similarly, a study that analyzed 925 patients from four Dutch hospitals found that 556 patients (60.1%) received antibiotic therapy, but only 12 patients (1.2%) had bacterial co-infection [99]. These data suggest that bacterial co-infections in COVID-19 patients are rare, and often these patients undergo antibiotic therapy even in the absence of bacterial infections. Consequently, antibiotics are empirically unnecessary and over-prescribed.

Antibiotics prescribed to COVID-19 patients are often broad-spectrum to ensure sensitivity to a wide range of suspect organisms. Among the most prescribed antibiotics are β-lactamases inhibitors, cephalosporins, fluoroquinolones, and macrolides [21, 104]. Azithromycin macrolide was the second most prescribed treatment for COVID-19 [12•]. Misinformation, in combination with the lack of treatment against COVID-19, has led many doctors to overprescribe antibiotics. In addition, educating physicians who treat COVID-19 patients with principles of antibiotic administration could decrease unnecessary antibiotic use.

The other reason for prescribing antibiotics in COVID-19 patients is the close similarity between COVID-19 pneumonia and bacterial pneumonia [72•]. The symptomatology described in patients with COVID-19 often overlaps with bacterial infections [105]. However, there are many difficulties differentiating pneumonia from bacterial or COVID-19 infection. Common biomarkers such as C-reactive protein or procalcitonin used to distinguish viral from bacterial pneumonia are often ineffective in patients with COVID-19. They require hours or days to obtain a result, making immediate treatment difficult [106]. C-reactive protein quantification is a rapid test to distinguish bacterial from viral pneumonia. C-reactive protein is a biomarker elevated in bacterial infections but not generally in viral infections. Before the COVID-19 pandemic, 90% of C-reactive protein elevations were attributed to infections whose etiologic agents were bacterial pathogens [107]. However, studies have shown that this biomarker can be increased in patients with COVID-19 [108], leading many clinicians to prescribe empiric antibiotics to patients with COVID-19 without a microbiological confirmation of bacterial infection. The research focused on the predictive value of diagnostic tools could considerably help in making clinical decisions when prescribing.

Lack of Availability of Diagnostic Tests

At a general level, the health system is lacking in identifying pathogens [109]. Antibiotics are often prescribed in medical care centers without a positive result of bacterial infection, contributing to the indiscriminate use of antibiotics and, therefore, the appearance of multidrug-resistant bacteria [109]. Antibiotics are also prescribed without knowing the pathogen causing the infection and the resistance profile, leading to the administration of ineffective treatments. Requesting diagnostic tests could resolve these issues. However, the most accepted diagnostic tests for microorganisms are based on microscopy, culture, and sensitivity. They need 24–48 h to show the result, which can discourage healthcare professionals from ordering laboratory tests [110]. Therefore, doctors often do not order antimicrobial tests before prescribing antibiotics, contributing to the indiscriminate use of antibiotics.

One option to combat this problem would be implementing diagnostic approaches based on molecular biology, which detect the pathogen’s DNA. These tests could ensure an early, accurate diagnosis and efficient antibacterial therapy for bacterial infections, thus avoiding fatal consequences such as the ineffectiveness of empirical treatments and increased multidrug-resistant strains [111]. However, implementing tests based on molecular biology still has some limitations, such as the high cost of the equipment used and the lack of availability in health centers in low- and middle-income countries [112]. This leads to the conclusion that we have the biotechnological tools available to make an adequate diagnosis, which helps to avoid the indiscriminate use of antibiotics. However, the economic deficiencies of the health system are still an obstacle. Greater investment is needed in the health system and antibiotic administration programs.

In this context, the implementation of molecular biological-based tests for the detection of bacteria during the COVID-19 pandemic could considerably help the easy and rapid identification of co-infections or secondary infections, leading to the administration of antibiotics only when necessary. The primary test for the diagnosis of COVID-19 is PCR (polymerase chain reaction). PCR is a susceptible and efficient molecular biology-based test that detects SARS-CoV-2 [113] or even Nanopore sequencing [114].

Despite the high costs of this test, during the COVID-19 pandemic, PCR was widely implemented in many countries, which considerably helped to diagnose many patients. However, the same patients were not analyzed for the presence of bacterial infections. Still, these same patients have often been prescribed antibiotics, which clearly shows the indiscriminate use of antibiotics during the COVID-19 pandemic. In addition, the accessibility and availability of these diagnostic tests will lead to a substantial decrease in the empirical administration of antibiotics.

Self-Medication and the COVID-19 Pandemic

Self-medication with antibiotics can lead to several public health problems, for example, the significant increase in antibiotic resistance. Self-medication is characterized by the inappropriate use of antibiotics by people who treat their illnesses without a prescription or medical supervision [115].

Since the beginning of the COVID-19 pandemic, preliminary studies in cell culture have suggested several drugs as promising candidates against SAR-CoV-2 [116]. For example, hydroxychloroquine, combined with azithromycin, has shown favorable results in cell culture trials and small, uncontrolled studies [117]. Many countries quickly spread news encouraging the use of hydroxychloroquine and azithromycin as a prophylactic or curative treatment against the new coronavirus [118], leading many people to self-medicate with various drugs, mainly antibiotics (azithromycin, ceftriaxone, and penicillins), and antiparasitics (chloroquine, hydroxychloroquine, nitazoxanide, ivermectin) during the COVID-19 pandemic [119]. However, evidence in hospitalized patients has shown that these drugs, as prophylactics or curatives, are ineffective against COVID-19 and can even be harmful [120, 121]. During the pandemic, the lack of knowledge and the massive spread of false news on social networks led many people to self-medicate with different medications, including antibiotics [121].

Self-medication with antibiotics is more frequent in low- and middle-income countries, where many antibiotics are freely sold, and counterfeiting antibiotics are more frequent [9, 12•]. Recently, a study reported that self-medication with antibiotics is more frequent in young people from low- and middle-income countries [9]. In another review study including 7676 participants, it was reported that all participants self-medicated with antibiotics in the last 3 months to 1 year before the study [122]. According to Ferdiana et al. [123], in Indonesia, participants reported using antibiotics without a doctor’s prescription because it was more convenient and cost-effective than looking for public healthcare or pay for a private consultation, mostly to treat common symptoms, as muscle relaxant and energy booster. There were reports of antibiotics that had already been prescribed by doctors, or by suggestions, even pharmacists. In India, the indiscriminate use of antibiotics is reported by the administration of different doses in public and private sectors [124]. In Sri Lanka, 77% of participants who reported self-medication with antibiotics had respiratory symptoms as a complaint [125].

Antibiotic access in developed countries is well regulated, and a prescription is required to dispense antibiotics [109]. However, in developing countries, the reality is different. In these countries, the policies to control and regulate antibiotic access are deficient [126, 127]. Antibiotics can be purchased over-the-counter, without a prescription at any pharmacy, or even when needed, they are sold freely due to lack of supervision [10, 123, 126, 128]. In the review carried out by Ocan et al. [129], most self-medication drugs are antibiotics and antimalarials, including chloroquine. In addition to using these drugs without a prescription, there are reports of shorter treatment times, wrong dosages, and misuse. The prevalence of self-medication found by Ocan et al. [129] was 38.8% in low- and middle-income countries, which corroborates the data found by Do et al. [126], where self-medication in these countries is 35%.

In 2020 in Peru, a study showed that 33.9% of hospitalized patients with COVID-19 self-medicated before entering the hospital, with the most frequent drugs being antibiotics (mainly azithromycin and ceftriaxone) and ivermectin [130]. On the other hand, a study conducted in Australia with 2217 participants revealed that during the first wave of the COVID-19 pandemic, approximately 20% of study participants self-medicated with antibiotics to protect themselves against COVID-19 [131]. In addition, a systematic review of eight cross-sectional studies found that the prevalence of self-medication with antibiotics ranged from 4 to 88.3% [121]. Therefore, implementing policies to educate the public about the problems associated with the indiscriminate use of antibiotics could help reduce self-medication. Consequently, it is crucial to use antibiotics appropriately, even during the pandemic, to avoid the appearance of multidrug-resistant strains.

A recent study in Mexico that evaluated changes in the resistance profile of critical and high-priority microorganisms collected before and during the COVID-19 pandemic showed an increase in antimicrobial resistance. This same study found a rise in oxacillin resistance by S. aureus and carbapenems by K. pneumoniae, as well as an increase in erythromycin macrolide resistance in S. aureus. The latter may be associated with excessive use of azithromycin [4•]. These results indicate that the COVID-19 pandemic strongly influenced the emergence of multidrug-resistant strains. However, we still do not have enough data to know the real impact of the COVID-19 pandemic on antimicrobial resistance. Therefore, more studies are needed to discover the real impact of the pandemic on antimicrobial resistance.

Conclusion

As analyzed in this review, bacterial pathogens from the ESKAPE group play a crucial role in turning bacterial infection into a fatal disease and being a deadly factor for COVID-19 patients. Even in the current pandemic scenario, bacterial co-infections with Gram-negative bacteria from the ESKAPE group are more common in patients with severe cases of COVID-19 than in patients with milder symptoms of the disease. Species in this group are commonly associated with highly virulent and antibiotic-resistant strains. As mentioned earlier, treating nosocomial infections caused by bacteria is still empirical, which may even contribute to the emergence of multidrug-resistant bacteria. In addition, the empirical prescription of antibiotics, self-medication, and the lack of availability of rapid diagnostic tests evidence the lack of control, government surveillance, and investment in the public health system, leading to the emergence of multidrug-resistant and the worsening of resistance of strains already known. More studies are still needed to know the actual damage of the COVID-19 pandemic. However, the data compiled in this study underscore the importance of epidemiological surveillance and analysis of the genetic evolution of hospital isolates to provide new strategies for preventing and controlling infections caused by multidrug-resistant bacteria. Furthermore, the bibliographic study also suggests that it is possible to mitigate this problem with coordinated efforts to implement new health policies based on the appropriate use of antibiotics, as well as the surveillance of the proper use of antibiotics, the training of medical personnel, and more significant investment in the health system and in research, which is undoubtedly a critical factor in the fight against antibiotic resistance and the development of new antibacterial agents.